Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus fruquintinib in selected solid tumors
CTR20211070Phase 2Completed
- Sponsor
- BeiGene
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, fruquintinib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, colorectal adenocarcinoma, non-small cell lung cancer (NSCLC), sponsored by BeiGene. Started May 2021; status: completed.
02
Drugs
tislelizumabfruquintinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomacolorectal adenocarcinomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20211070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211070.